Business ❯ Pharmaceutical Industry

Vaccine Market

RSV Vaccines Moderna Profitability Competitive Landscape Regulatory Approvals Flu Vaccine Sales Market Withdrawal Moderna's Financials Moderna Inc. Funding Strategies

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

The company says the setback does not change its financial outlook.

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial